ERBB2 and breast cancer: In another study, BET inhibition was also able to suppress lapatinib-induced transcriptional induction of a large portion of tyrosine kinases including those identified to contribute to growth (HER3, DDR1, FGFR2 and MET) in HER2+ BC cells[72], preventing downstream SRC/FAK signalling and AKT reactivation.